Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients
Patients receiving >100 Gy of Rhenium (186Re) Obisbemeda achieved a median overall survival of 17 months, more than double the 8-month median overall survival with standard of care
HOUSTON, March 07, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ('Plus' or the 'Company'), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the publication of results in a peer-reviewed manuscript titled, "Treatment of Recurrent Glioma by Rhenium (186Re) Obisbemeda (186RNL): a Phase 1 clinical trial" in the peer-reviewed medical journal Nature Communications.
'Peer-reviewed publication of our Phase 1 glioma data in a prestigious, high-impact factor journal is substantial validation for this important clinical program,' said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. 'Based largely on this data, our ReSPECT-GBM Phase 2 trial is currently enrolling patients at leading medical centers, bringing us closer to delivering a much-needed treatment option for this devastating disease.'
Key highlights from the publication:
Twenty-one patients were treated with doses up to 22.3 mCi of Rhenium (186Re) Obisbemeda
No dose-limiting toxicity was observed, and most adverse events were unrelated to the study treatment
Median overall survival (OS) was 11 months, surpassing the standard of care for recurrent glioblastoma, which is approximately 8 months
Median OS was strongly correlated with radiation absorbed dose to the tumor and the percentage of tumor treated
Patients receiving >100 Gy (n=12) had a median OS of 17 months, compared to 6 months for those receiving <100 Gy (n=9) (p=0.001)
Absorbed radiation doses to the tumor were as high as 739.5 Gy and were delivered without significant toxicity, exceeding levels achievable with external beam radiation therapy
The full manuscript can be accessed here.
The ReSPECT-GBM trial is actively enrolling patients; additional information about the ReSPECT-GBM trial can be found here.
About Recurrent Glioblastoma (GBM)
GBM affects approximately 15,000 patients annually in the U.S. and is the most common and lethal form of brain cancer. The average life expectancy with GBM is less than 24 months, with a one-year survival rate of 40% and a five-year survival rate of around 5%. There is no clear standard of care for recurrent GBM and the few currently approved treatments provide only marginal survival benefit and are associated with significant side effects, which limit dosing and prolonged use. Approximately 90% of patients experience GBM tumor recurrence at or near the original tumor location, yet there are no FDA-approved treatments in the recurrent or progressive setting that can significantly extend a patient's life.
About Rhenium (186Re) Obisbemeda
Rhenium (186Re) Obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. Rhenium (186Re) Obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) Obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
About Convection-Enhanced Delivery
Convection Enhanced Delivery (CED) is a therapeutic strategy that was developed to facilitate targeted delivery of pharmaceuticals to the brain. The CED procedure involves a minimally invasive surgical exposure of the brain, followed by placement of small diameter catheters directly into the brain tumor.
About Plus TherapeuticsPlus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking StatementsThis presentation contains statements that may be deemed 'forward-looking statements' within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as 'potential,' 'anticipating,' 'planning' and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of Rhenium (186Re) Obisbemeda including the ability of Rhenium (186Re) Obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company's future performance including the next steps in developing the Company's current assets; the Company's clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM, ReSPECT-LM and ReSPECT-PBC, clinical trials; possible negative effects of Rhenium (186Re) Obisbemeda; the continued evaluation of Rhenium (186Re) Obisbemeda including through evaluations in additional patient cohorts; the intended functions of the Company's platform and expected benefits from such functions; and the development, utility and potential of the CNSide leptomeningeal metastases diagnostic test.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company's product candidates and therapies, the results of the Company's research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's liquidity and capital resources and its ability to raise additional cash, the outcome of the Company's partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms, and material security breach or cybersecurity attack affecting the Company's operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics' business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics' annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC's website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor ContactCharles Y. Huang, MBADirector of Capital Markets and Investor RelationsOffice: (202)-209-5751 | Direct (301)-728-7222chuang@plustherapeutics.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
21 minutes ago
- Business Upturn
Syntiant to Demonstrate Ultra-Low-Power Automotive AI Innovations at AutoSens and InCabin 2025
IRVINE, Calif., June 10, 2025 (GLOBE NEWSWIRE) — Syntiant Corp., the recognized leader in low-power edge AI deployment, today announced it will showcase two of its vehicle sensing technologies at AutoSens and InCabin 2025, June 10-12 at Huntington Place in Detroit (Booth #210). Syntiant's multimodal automotive solutions are designed to enhance vehicle safety and user experiences by enabling always-on audio and vision intelligence at the edge, without draining the battery or relying on cloud connectivity. Live demonstrations will include: Low-power camera security system . Ideal for applications such as parked vehicle monitoring and fleet management, this AI perimeter security solution keeps dash or external cameras in an ultra-low-power standby mode while continuously monitoring for specific audio or visual cues, such as footsteps, voices or motion near the vehicle. Upon detection, the system instantly activates high-resolution cameras to begin recording at under 200 mW, preserving energy while improving real-time incident capture. In contrast, traditional always-on security systems can draw over 100 watts , limiting them to electric vehicles with large batteries. Syntiant's solution delivers comparable performance at a fraction of the power, enabling always-on security for virtually any vehicle. . Ideal for applications such as parked vehicle monitoring and fleet management, this AI perimeter security solution keeps dash or external cameras in an ultra-low-power standby mode while continuously monitoring for specific audio or visual cues, such as footsteps, voices or motion near the vehicle. Upon detection, the system instantly activates high-resolution cameras to begin recording at under 200 mW, preserving energy while improving real-time incident capture. In contrast, traditional always-on security systems can draw over 100 watts limiting them to electric vehicles with large batteries. Syntiant's solution delivers comparable performance at a fraction of the power, enabling always-on security for virtually any vehicle. External sound detection using vibration sensors. Traditional microphones placed outside of a vehicle are prone to failure in harsh environments. Rain, dust, snow and even car washes might permanently damage the device. Syntiant's V2S vibration sensors mounted on a vehicle's door, windshield or trunk, detect motions caused by external sounds, enabling features like emergency vehicle detection and hands-free voice commands (e.g., 'open trunk'), without the exposure-related limitations of conventional microphones. By effectively turning the vehicle's surface into the microphone, the Syntiant V2S provides a durable and reliable alternative for external sound detection. 'Enhanced sensing capabilities are essential to meet the demands of smarter vehicles, especially when driving conditions are less than ideal,' said Greg Doll, SVP and GM of Syntiant's sensors business unit. 'By integrating sensors, AI hardware and software, we have developed low-power automotive intelligence that can enable vehicles to be more responsive to their surroundings, and ultimately more useful to drivers and passengers.' Syntiant's complete automotive solutions are powered by a combination of its Neural Decision Processors, ML models, sensors and microphones. These technologies power a broad range of intelligent automotive features, including voice and siren detection, blind spot alerts, facial recognition, battery management, in-cabin monitoring and other Advanced Driver Assistance Systems (ADAS). More information about Syntiant's automotive solutions can be found at AutoSens and InCabin 2025 OEMs and Tier 1 suppliers can register at no cost by visiting Partners, including distributors, representatives and design partners, are eligible for a 30% discount, available upon request by emailing [email protected]. To schedule a private demo or meeting with Syntiant (Booth #210), please contact [email protected]. About Syntiant Founded in 2017 and headquartered in Irvine, Calif., Syntiant® is Making Edge AI a Reality™ by delivering highly efficient processor, sensor and software solutions. With more than 100 million purpose-built silicon and ML models deployed, along with billions of MEMS microphones and sensors, Syntiant's technology is powering edge AI applications for speech, audio, sensor and vision processing worldwide. From earbuds to automobiles, the company's turnkey solutions enable advanced edge AI capabilities across diverse consumer and industrial use cases. More information on the company can be found by visiting or by following Syntiant on X @Syntiantcorp or LinkedIn. Media Contact: George Medici/Natalie MuPondelWilkinson Inc. [email protected] or [email protected] 310-279-5968
Business Upturn
21 minutes ago
- Business Upturn
Ontario, Canada Filtration Manufacturer Camfil Demonstrates Significant Cost Savings for Ontario School Air Filtration Systems
Toronto, Ontario, June 10, 2025 (GLOBE NEWSWIRE) — Camfil Canada, a leading provider of commercial and industrial air filtration solutions, today announced the publication of a comprehensive case study demonstrating substantial cost savings achieved through advanced air filter implementation in Ontario school facilities. The research highlights how Canadian educational institutions can reduce operational expenses while improving indoor air quality for students and staff. Addressing Canadian School Air Quality Challenges Ontario schools face unique air quality management challenges, including extreme seasonal temperature variations, budget constraints, and increasing focus on student health and improving the learning environment. The new case study provides a detailed analysis of how proper air filter selection and implementation can address these challenges while delivering measurable financial benefits. 'Canadian schools operate under significant budgetary pressures while maintaining responsibility for student and staff health,' said Joshua Gutherie, Air Quality Expert at Camfil Canada. 'Our case study demonstrates that investing in high-efficiency air filtration technology delivers both improved air quality and substantial cost savings for Ontario schools.' Documented Cost Savings in Ontario Educational Facilities The published case study presents a detailed financial analysis of implementing the plan for Ontario schools, including: ● Energy Cost Reductions: Quantified savings in heating and cooling expenses through improved HVAC system efficiency ● Maintenance Cost Decreases: Reduced filter replacement frequency and HVAC system maintenance requirements ● Extended Equipment Life: Protection of HVAC systems leading to deferred capital replacement costs ● Operational Efficiency Improvements: Streamlined maintenance procedures and reduced labour requirements The study specifically addresses the impact of Ontario's energy costs and seasonal operational demands on the performance and economics of school air filtration systems. Supporting Student Health and Learning Outcomes Beyond cost savings, the case study documents improvements in indoor air quality that directly benefit student health and academic performance. Research continues to demonstrate the connection between improved air quality and enhanced learning environments, making air filtration investments valuable from both financial and educational perspectives. 'Ontario schools are increasingly recognizing that air quality investments support both fiscal responsibility and educational excellence,' noted Guthrie. 'Our case study provides the data and analysis that school boards need to make informed decisions about air filtration technology.' Advanced Filtration Solutions for Canadian Schools The case study features a detailed analysis of air filtration technologies specifically suited to Canadian educational environments, including: ● High-Efficiency Particulate Filters: Engineered to handle Ontario's seasonal allergen and particulate loads while minimizing energy consumption ● Extended Service Life Filters: Designed to maintain performance despite challenging Canadian environmental conditions. This includes fewer replacements, with some filters lasting up to a year in Ontario schools, compared to three months for competing filters. ● Energy-Efficient Filter Media: Optimized for Canadian HVAC systems and operations ● Each solution addresses the specific requirements of Ontario schools, including compliance with provincial building codes, accommodating extreme temperature variations, and optimizing energy cost savings. Practical Implementation Guidance for Ontario School Boards The published case study provides actionable implementation strategies for Ontario educational facilities, addressing common concerns, including: ● Budget Planning: ROI calculations and payback period analysis for different filter upgrade scenarios ● Seasonal Considerations: Implementation of timing recommendations for Ontario school operational schedules ● Maintenance Training: Guidance for school staff on optimizing filter performance and longevity ● Compliance Requirements: Alignment with Ontario building codes and educational facility standards Supporting Ontario's Educational Infrastructure The case study reflects Camfil Canada's commitment to supporting Ontario's educational sector through practical air quality solutions that address both health and financial priorities. As Ontario schools continue to focus on creating optimal learning environments while managing operational costs, evidence-based air filtration strategies provide measurable benefits. The research also addresses emerging considerations for Ontario schools, including enhanced focus on indoor air quality following public health awareness campaigns and increasing emphasis on energy efficiency in public buildings. Canadian Educational Resource Availability The complete Ontario schools air filtration case study is available now through Camfil Canada's website at The resource includes downloadable implementation guides, cost calculation tools, and technical specifications specifically developed for Canadian educational facilities. About Camfil Canada Ontario, Canada Filtration Manufacturer Camfil Camfil Canada is a leading provider of air filtration solutions for commercial, industrial, and institutional applications across Canada. With comprehensive experience in Canadian building environments, the company provides engineered solutions for challenging air quality requirements, including educational facilities, healthcare institutions, commercial buildings, and industrial operations. The company maintains distribution and service capabilities across Canada, providing technical support, installation guidance, and maintenance services from coast to coast. Camfil Canada is part of the global Camfil Group, recognized worldwide for innovation in air filtration technology and commitment to clean air solutions. For more information about Camfil Canada's educational facility air filtration solutions, visit the Camfil Canada Website or contact the Canadian educational applications team at 905-660-0688. Media Contact: Phillip Ilijevski Camfil Canada Inc. Phone: 437-929-1161 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Upturn
21 minutes ago
- Business Upturn
Lucasys Income Tax Suite Launches on SAP® Store
By GlobeNewswire Published on June 10, 2025, 22:29 IST ATLANTA, June 10, 2025 (GLOBE NEWSWIRE) — Lucasys, a leading cloud software and service provider for rate-regulated utilities, today announced that its suite of tax applications – including Lucasys Tax Depreciation, Deferred Tax, TBBS, and Copilot – is now available on the SAP® Store, the digital marketplace for SAP and partner offerings. This milestone follows Lucasys' recent partnership within the SAP® PartnerEdge® Open Ecosystem. By integrating with SAP S/4HANA® and other SAP solutions, these applications provide a seamless experience for customers managing complex tax and regulatory requirements. 'Bringing Lucasys Tax applications to the SAP Store underscores our commitment to fostering innovation and flexibility for utilities and asset-intensive businesses,' said Daniel Chang, Chief Operating Officer at Lucasys. 'With this integration, customers can enhance their SAP environments with modern, purpose-built tax solutions that simplify processes, improve compliance, and unlock actionable insights.' Lucasys' tax applications are designed to streamline and automate critical tax processes, including tax depreciation and deferred tax management, while delivering unparalleled usability and security. The modular architecture and deep regulatory support of these solutions ensure that customers can adapt to changing industry demands and achieve long-term operational excellence. Key Features of the Lucasys Income Tax Suite: Integrated Tax Applications: Single integrated experience across tax applications used for tax accounting, tax compliance, and tax forecasting. Enhanced Usability: Simplified workflows reduce the data maintenance burden for end users and facilitate onboarding and training. Flexible Reporting: Robust, user-driven reporting allows for greater visibility and data confidence. Data-Driven Insights: Provides actionable analytics to facilitate strategic tax planning. Scalable Solutions: Tailored for large enterprises and asset-intensive organizations. To learn more about Lucasys' solutions and their availability in the SAP Store, visit and SAP® Store. About Lucasys Lucasys provides software and technology-enabled services to empower finance, accounting, and tax professionals in asset-intensive industries to optimize the financial performance of their fixed assets and proactively meet changing regulatory and compliance requirements. With a core focus on rate-regulated utilities, Lucasys provides the industry and domain expertise utilities require to meet their business objectives. To learn more about Lucasys, visit A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
